Opendata, web and dolomites

REGHA

Medical device combining viscosupplementation with pharmacological active molecule to regenerate cartilage in degenerative or traumatic osteoarthritis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REGHA project word cloud

Explore the words cloud of the REGHA project. It provides you a very rough idea of what is the project "REGHA" about.

breakthrough    adults    manufacturing    completion    join    highest    treatment    degree    degenerative    formulation    market    economic    contain    packaging    chondrocytes    people    solution    local    degeneration    roi    therapeutic    affordable    aging    unmet    active    phases    producing    stimulating    proliferation    10    patented    combination    injuries    health    batch    surgery    innovative    business    commercial    oa    biological    commercialize    vessels    molecules    easily    combining    million    cheaper    social    osteoarthritis    plan    glp    therapy    cells    maintaining    15    cartilage    commercialization    feasibility    viscosupplementation    regenerative    altogether    injection    device    molecule    globally    matrix    combined    production    locally    strategy    concerning    final    injectable    subsequent    md    medical    found    population    blood    disease    burden    positive    planning    undertaken    administered    innovation    frequent    refined    clinical    pharmacological    validation    joint    huge    worldwide   

Project "REGHA" data sheet

The following table provides information about the project.

Coordinator
REGULAXIS 

Organization address
address: 102 AVENUE GASTON ROUSSEL
city: ROMAINVILLE
postcode: 93230
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.regulaxis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGULAXIS FR (ROMAINVILLE) coordinator 50˙000.00

Map

 Project objective

To develop and commercialize a medical device (MD) that can effectively respond to unmet therapeutic needs in the treatment of osteoarthritis (OA), namely degeneration of cartilage. OA is a huge medical, social and economic burden worldwide. This therapeutic approach by local injection in the join will be a breakthrough innovation for OA therapy. The expected product is a combination of HA viscosupplementation with our pharmacological active patented molecule stimulating chondrocytes proliferation, the only cells producing and maintaining the cartilage matrix. Cartilage does not contain blood vessels, therefore this requires the product be administered locally. Our innovative project will provide a MD allowing an easily, affordable and cheaper solution than surgery for the therapeutic treatment of OA and should have a positive impact on the economic and social cost of OA. The commercial potential is one of the highest in the field of health because there are currently no specific therapeutic molecules on the market for this frequent degenerative disease. Users are to be found in the aging population and people with joint injuries in need for a regenerative therapy. The feasibility assessment undertaken in Phase I will be the completion of the technical feasibility studies for combining our molecule with HA in an injectable solution, for formulation and production of the combined products including validation of its biological activities and the selection of manufacturing partners for the MD final production (processes for production of the final GLP batch and packaging will be assessed) allowing the subsequent planning & implementation of manufacturing for clinical phases. The commercialization plan will be refined using detail analysis of potential users, ROI for the different business cases and the best strategy for commercialization In Europe altogether 10%-15% of adults over 60 have some degree of OA globally estimated concerning more than 70 million of people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REGHA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REGHA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More